A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding
Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
The study is designed to assess the efficacy and safety of famciclovir 250 mg twice a day
(bid) suppressive treatment in men and women with herpes virus type 2 (HSV-2) infection, with
and without a reported history of genital herpes and with or without herpes virus type 1
(HSV-1) seropositivity.